Answers are grounded in this paper and cite their sources.
Bayesian adaptive designs enable flexible clinical trials by adapting features based on accumulating data. Among these, Bayesian Response-Adaptive Randomisation (BRAR) skews patient allocation towards more promising treatments based on interim data. Implementing BRAR requires the relatively quick evaluation of posterior probabilities. However, the limitations of existing closed-form solutions mean trials often rely on computationally intensive approximations which can impact accuracy and the scope of scenarios explored. While faster Gaussian approximations exist, their reliability is not guaranteed. Critically, the approximation method used is often poorly reported, and the literature lacks practical guidance for selecting and comparing these methods, particularly regarding the trade-offs between computational speed, inferential accuracy, and their implications for patient benefit. Focusing on BRAR trials with binary endpoints, a novel algorithm is developed that efficiently and exactly computes these posterior probabilities, enabling a robust assessment of existing approximation methods in use. Leveraging these exact computations, a comprehensive benchmark is established for evaluating approximation methods based on their computational speed, patient benefit, and inferential accuracy. The comprehensive analysis, conducted through a range of simulations and a re-analysis of a real-life multi-arm trial, reveals that the exact calculation algorithm is highly efficient and often the fastest approach for trials with a small to moderate number of arms. Furthermore, it is demonstrated that commonly used approximation methods can lead to significant power loss and type I error rate inflation, with the Gaussian approximation emerging as a particularly unreliable option. To address the exponential scaling inherent in exact multi-arm computations, a formal, quantitative framework is provided. This practical guidance equips practitioners with precise thresholds to seamlessly transition between exact calculations and safe approximation methods across various clinical trial settings.
No takes yet. Share an insight, caveat, or question.
Kaddaj et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: